The Vote Is Thursday. Here's What's Actually at Stake.

The FDA's Vaccines and Related Biological Products Advisory Committee — known as VRBPAC — meets Thursday, May 29, to vote on whether COVID-19 vaccines should be updated to target the XFG subvariant for the 2026-27 respiratory season.

The panel will weigh real tradeoffs in its decision.

What the Data Says

According to CDC data cited by Reuters, the XFG subvariant was estimated to account for a majority of U.S. COVID cases over the four-week period ending April 11, 2026. That's a significant share of active transmission.

XFG, like all current variants, is still descended from the JN.1 strain. But new subvariants — NB.1.8.1 and XFG — have emerged since May 2025, according to documents filed with the FDA on Tuesday.

For the 2025-26 season, the FDA had recommended vaccines target LP.8.1, a different JN.1 subvariant. That formula is already being overtaken by events on the ground.

WHO and FDA Aren't on the Same Page

Earlier this month, the World Health Organization recommended manufacturers target LP.8.1 — the same strain used for 2025-26 — while noting that "other antigens such as XFG or NB.1.8.1 could also be used," according to the VRBPAC briefing document reported by The Hill.

The U.S. is no longer a member of the WHO, as noted by AOL/The Hill. That means the FDA isn't bound by the recommendation and can pursue a different course.

The WHO's recommendation to stay with LP.8.1 while XFG is already dominating U.S. cases raises an obvious question: How does chasing last season's strain make any sense?

The Manufacturers Are Ready

All three authorized COVID vaccine manufacturers — Pfizer-BioNTech, Moderna, and Novavax (now licensed to Sanofi in a deal worth up to $1.2 billion) — have told the FDA they are prepared to produce an XFG-targeted vaccine for 2026-27, according to FDA briefing documents cited by Reuters.

Sanofi, Pfizer, and Moderna are all scheduled to present to the advisory committee Thursday.

One important technical note: Novavax's protein-based shot takes longer to manufacture than the mRNA vaccines from Pfizer and Moderna. That matters for timelines. The FDA's own briefing acknowledged that "timelines likely differ for different manufacturing technologies."

Leadership Vacuum at the FDA — Right Now

This vote happens at a uniquely unstable moment for the agency.

Former FDA Commissioner Marty Makary resigned roughly two weeks ago. His tenure included stricter requirements for COVID vaccine use and public battles with drugmakers over drug and vaccine reviews — making him a polarizing figure who drew fire from both pharma and public health circles.

Deputy Commissioner for Food Kyle Diamantas is now running the agency in an acting capacity, according to Reuters.

Vaccine chief Vinay Prasad, who shared Makary's skepticism of broad COVID vaccine mandates and policies, also recently stepped down. Karim Mikhail was named acting director of the FDA's vaccines and biologics unit earlier this month.

Three leadership changes in rapid succession — commissioner, vaccine chief, biologics director — are happening right before a major vaccine formulation vote.

What Mainstream Coverage Is Missing

Most coverage is treating this as a routine annual vaccine update story. The fuller picture reveals different layers.

VRBPAC itself was quietly reshaped after HHS Secretary Robert F. Kennedy Jr. took office. According to The Hill/AOL, prominent vaccine committee member Dr. Paul Offit — a vocal Kennedy critic — was removed from the committee last September. He said publicly he was given no reason for his dismissal.

The committee that votes Thursday is not the same committee that existed two years ago. Whether that's a positive or negative development depends on one's perspective — but the change itself is significant.

Also absent from most headlines: XFG is still classified by the WHO as a "variant under monitoring" — the lowest of three threat tiers. That doesn't mean it's harmless. It means the global scientific community hasn't elevated it to "variant of interest" or "variant of concern" status yet. Context matters.

XFG Is a Variant Under Monitoring — But It's Already Dominant

A strain the WHO hasn't even promoted to its middle threat tier is already accounting for the majority of U.S. COVID cases. Either the WHO's classification system lags behind reality, or the U.S. is seeing a localized surge that global data doesn't fully reflect yet.

The FDA advisers will have to make a judgment call with incomplete information and a manufacturing deadline bearing down on them.

What This Means for You

If the panel votes Thursday to update the formula to XFG, manufacturers will move to retool production. The 2026-27 COVID vaccine — assuming it gets a vote to move forward — would target the strain that is actually circulating now rather than last year's dominant variant.

For those who get the annual COVID shot, a correctly targeted vaccine is preferable to a mismatched one.

For those skeptical of annual COVID vaccine campaigns, the composition doesn't change the underlying question — though credible, accountable leadership with stable governance should matter regardless of one's vaccine stance.

Right now, the FDA has acting leadership across its most critical vaccine positions, a reshuffled advisory committee, and a vote Thursday that will shape what goes into hundreds of millions of doses.

Watch who shows up Thursday and what they say.